Eton Pharmaceuticals Stock Alpha and Beta Analysis
| ETON Stock | USD 12.03 0.80 7.12% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Eton Pharmaceuticals. It also helps investors analyze the systematic and unsystematic risks associated with investing in Eton Pharmaceuticals over a specified time horizon. Remember, high Eton Pharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Eton Pharmaceuticals' market risk premium analysis include:
Beta 1.26 | Alpha 1.4 | Risk 4.05 | Sharpe Ratio 0.39 | Expected Return 1.59 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Eton |
Eton Pharmaceuticals Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Eton Pharmaceuticals market risk premium is the additional return an investor will receive from holding Eton Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Eton Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Eton Pharmaceuticals' performance over market.| α | 1.40 | β | 1.26 |
Eton Pharmaceuticals expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Eton Pharmaceuticals' Buy-and-hold return. Our buy-and-hold chart shows how Eton Pharmaceuticals performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Eton Pharmaceuticals Market Price Analysis
Market price analysis indicators help investors to evaluate how Eton Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Eton Pharmaceuticals shares will generate the highest return on investment. By understating and applying Eton Pharmaceuticals stock market price indicators, traders can identify Eton Pharmaceuticals position entry and exit signals to maximize returns.
Eton Pharmaceuticals Return and Market Media
The median price of Eton Pharmaceuticals for the period between Wed, Aug 28, 2024 and Tue, Nov 26, 2024 is 7.83 with a coefficient of variation of 28.38. The daily time series for the period is distributed with a sample standard deviation of 2.07, arithmetic mean of 7.28, and mean deviation of 1.81. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Eton Pharmaceuticals assumed with a Buy at H.C. Wainwright - TipRanks | 09/04/2024 |
2 | Discretionary transaction by Opaleye Management Inc. of tradable shares of Eton Pharmaceuticals subject to Rule 16b-3 | 09/09/2024 |
3 | Acquisition by Opaleye Management Inc. of 5000 shares of Eton Pharmaceuticals at 4.75 subject to Rule 16b-3 | 09/11/2024 |
4 | Acquisition by David Krempa of 42088 shares of Eton Pharmaceuticals subject to Rule 16b-3 | 10/02/2024 |
5 | Acquisition by Opaleye Management Inc. of 1852 shares of Eton Pharmaceuticals at 6.771 subject to Rule 16b-3 | 10/04/2024 |
6 | Is Eton Pharmaceuticals A Risky Investment | 10/07/2024 |
7 | Acquisition by Opaleye Management Inc. of 70 shares of Eton Pharmaceuticals at 7.0292 subject to Rule 16b-3 | 10/08/2024 |
8 | Eton Pharmaceuticals, Inc. Major Shareholder Opaleye Management Inc. Acquires 11,248 Shares | 10/11/2024 |
9 | Acquisition by Opaleye Management Inc. of 10000 shares of Eton Pharmaceuticals at 7.9814 subject to Rule 16b-3 | 10/23/2024 |
10 | Eton Pharmaceuticals PT Raised to 15.00 | 10/28/2024 |
11 | Eton Pharmaceuticals Awarded Second Patent for ET-400 | 11/07/2024 |
12 | Eton Pharmaceuticals growing losses dont faze investors as the stock spikes 16 percent this past week | 11/12/2024 |
13 | Investors Appear Satisfied With Eton Pharmaceuticals, Inc.s Prospects As Shares Rocket 29 | 11/14/2024 |
14 | Short Interest in Eton Pharmaceuticals, Inc. Drops By 6.2 | 11/18/2024 |
15 | Eton Pharmaceuticals Inc Stock Price Up 4.34 percent on Nov 19 | 11/19/2024 |
16 | Eton Pharmaceuticals Announces Acquisition of U.S. Rights to Amglidia | 11/25/2024 |
About Eton Pharmaceuticals Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Eton or other stocks. Alpha measures the amount that position in Eton Pharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2023 | 2024 (projected) | Dividend Yield | 0.024 | 0.0214 | Price To Sales Ratio | 3.55 | 3.37 |
Eton Pharmaceuticals Upcoming Company Events
As portrayed in its financial statements, the presentation of Eton Pharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Eton Pharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Eton Pharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Eton Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Eton Pharmaceuticals' management manipulating its earnings.
| 21st of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 21st of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Eton Pharmaceuticals
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Eton Pharmaceuticals Backtesting, Eton Pharmaceuticals Valuation, Eton Pharmaceuticals Correlation, Eton Pharmaceuticals Hype Analysis, Eton Pharmaceuticals Volatility, Eton Pharmaceuticals History and analyze Eton Pharmaceuticals Performance. To learn how to invest in Eton Stock, please use our How to Invest in Eton Pharmaceuticals guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Eton Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.